Proscia, a provider of automated and computational pathology solutions, and Ibex Medical Analytics, a cancer diagnostics company focused on artificial intelligence (AI), have formed a strategic alliance to help pathologists diagnose prostate cancer.
The partners will advance the use of computationally enabled workflows leveraging AI to improve accuracy, performance, and quality in routine diagnostic pathology workflows resulting from their collaboration.
The pathologist’s examination of tissue biopsies under the microscope is the gold standard for cancer diagnosis. Prostate cancer diagnosis from a biopsy is difficult since it necessitates the pathologist examining a large number of samples to find tumor foci that are often subtle, minute and rely on a qualitative grading system to evaluate disease severity. This review process will result in more pathologists being used, missing diagnosis, dependence on ancillary testing, and a lack of faith in care decisions.
Proscia and Ibex have collaborated to develop a single software solution that drives AI-enabled workflows for prostate cancer diagnosis, enabling laboratories to achieve substantial efficiency and quality improvements. The joint product integration will put Ibex’s Galen Prostate solution together with Proscia’s Concentric image and data management platform, incorporating AI-powered prostate core needle biopsies triaging, cancer detection, and grading into routine workflows. Galen Prostate is now in use in laboratories worldwide, providing pathologists with real-time quality control by alerting them to cancers that have been misdiagnosed or graded incorrectly.
Joseph Mossel, CEO, and co-founder, Ibex Medical Analytics, said: “As prostate cancer impacts millions of patients each year, and as pathologists face ever-increasing challenges, it is paramount that we empower laboratories with clinical-grade AI solutions that provide accurate, timely diagnosis and ultimately improve patient outcomes. We are excited to partner with Proscia to accelerate the development and rollout of end-to-end digital pathology solutions that utilize the full potential of our AI technology.”
Laboratories and health systems use Proscia’s Concentriq for routine image viewing, management, analysis, and a launchpad for computational applications. Galen Prostate will be made available to Concentric consumers, beginning with a small number of customers in the United States and Europe. Concentriq will integrate AI insights provided by Galen Prostate into laboratories’ linked digital environments since it also operates with scanners and laboratory information systems (LIS), with integrations with Philips, Leica, 3DHISTECH, and Hamamatsu.
Dave West, CEO of Proscia, said: “Computational pathology is poised to make the biggest impact on the field since the introduction of the microscope over a century ago. Our partnership with Ibex helps laboratories to capitalize on this promise by seamlessly deploying a solution backed by great science and proven customer success into workflows at scale.”
